Therapeutic Use Exemptions Under Golf Australia’s Anti-Doping Policy
The fol owing information provides an outline of the approval process for Therapeutic
Use Exemptions under the Golf Australia’s Anti-Doping Policy. Any player participating
in a Golf Australia Championship, or any other tournament that carries a condition for
drug testing under Golf Australia’s Anti-Doping Policy, wil be required to apply for a
therapeutic use exemption as listed below if they are taking a substance banned under
Firstly, to determine the rules under our Anti-Doping Policy, you should check with the
approved Golf Australia Anti-Doping Policy listed on our website
(www.golfaustralia.org.au). The Policy is updated from time-to-time to conform to World
To check the status of an actual substance, it is recommend you cal the Australian Sports Anti-Doping Agency Hotline on 1800 020 506 to determine if the substance is
banned under our Policy. This is a free service that operates 9.00am – 5.00pm
weekdays Eastern Australian Time. The ASADA Hotline operator wil provide you with
the status advice and a cal reference number.
Medications and substances can also be checked outside the above hours on the
WADA website (www.wada-ama.org) or by obtaining a current copy of ASADA’s Anti-Doping Handbook. The WADA List of Prohibited Substances is reviewed at least
There are two different classes of Therapeutic Use Exemptions available under WADA
anti-doping rules, Standard and Abbreviated. Listed below is the approval process for
each and both forms are available on our website.
Standard Therapeutic Use Exemptions
Players with a documented medical condition requiring the Use of a Prohibited
Substance or a Prohibited Method must first obtain a Therapeutic Use Exemption (TUE)
in accordance with the WADA International TUE Standard. In Australia, this means that
an application on an ASDMAC Application Form must be made to the Australian Sports
Drug Medical Advisory Committee (ASDMAC). The Form is available from the ASDMAC
website (www.asdmac.org.au) or the Golf Australia website (www.golfaustrlia.org.au)
The application can be submitted directly to ASDMAC by an athlete or via Golf
Australia. In either case, Golf Australia wil be informed about the result only if an
exemption is approved. ASDMAC contact details are:
In regard to Standard TUE applications, the fol owing points should be noted:
• A fully completed, signed original ASDMAC application form must be
submitted. The original athlete signature is necessary for ASDMAC to comply
with Australian privacy legislation. The Medical Practitioner’s signature is also
• Sufficient supporting clinical documentation must be provided with the application
to meet the strict criteria which is required before approval can be granted. The
supporting clinical information should include a full clinical history, investigations and test results and information as to failed treatment with permitted medications.
• ASDMAC wil mail formal confirmation of its TUE decision to the applicant.
The Standard TUE Process wil take approximately 21 working days to assess once an
application has been received by ASDMAC. Their assessment process involves
sending copies of the application and documentation to 5 medical practitioners for
Urgent and emergency therapeutic use exemptions
If approval is required in less than seven days (urgent) or treatment must be
commenced immediately (emergency) then the ASDMAC procedure below should be
In-office hours (9.00am-5.30pm weekdays)
• Phone ASDMAC secretariat on (02) 6206 0232. • If necessary, the treating doctor may discuss the case with an ASDMAC
• In emergency cases a provisional TUE approval may be given over the phone.
Such approval may be subject to conditions.
• Approval, if granted, wil be formalised when the ASDMAC standard TUE
application form and al supporting documentation is submitted to ASDMAC’s
secretariat within a permitted timeframe.
Out-of-office hours (including weekends and public holidays)
• Email [email protected] or fax the ASDMAC secretariat on (02) 6206 0262
with ful details of the case to be considered including the medication used,
condition prescribed for and contact details.
• You wil be contacted by the ASDMAC secretariat and the above process wil be
• If necessary, the treating doctor may discuss the situation with an ASDMAC
ASDMAC also mention that in an emergency or urgent situation it is important to
remember that the treating medical practitioner should use his or her clinical judgment
and treat the patient first. If time is available, consideration should be given to the use of
Abbreviated Therapeutic Use Exemptions (ATUE) Abbreviated TUE’s are managed by Golf Australia and therefore the Golf Australia
Abbreviated Application Form must be submitted to Golf Australia, not ASDMAC.
Substances covered by the abbreviated process include:
- an inhaled asthma medication (formoterol, salbutamol, salmeterol, terbutaline)
- a non-systemic glucocorticosteroid (anal, aural, inhalation, intra-articular, nasal
and ophthalmological administration; glucocorticosteroids are contained in some
In regard to ATUE applications, the fol owing points should be noted:
• A fully completed, signed original ATUE application form must be submitted to Matt Cutler at Golf Australia. The original athlete and their
medical practitioner’s signatures are required. (Please mark the application
• The medical practitioner must provide information concerning symptoms, tests
and diagnosis under the Medical Information Section.
• Once the information is received I wil put the athletes’ details on our ATUE
For further information regarding TUE's or any other Anti-Doping matters please contact
Matt Cutler - High Performance at Golf Australia on 03 9626 5050.
Dos relatos, un análisis y un excurso sobre las identidades y la relación con la ciudad entre los “moradores de la calle” en Temuco, Chile1 Two tales, an analysis and an excursus on identities and the relationship with the city among “street-dwellers” in Temuco, Chile Aceptación: 15 diciembre 2009Aprobación: 25 abril 2010 El autor describe dos casos de pe
Methotrexat “Ebewe” 2. Composition 1 ampoule of 1ml contains 5mg methotrexate as active ingredient. 1 vial of 1ml contains 5mg methotrexate as active ingredient. 1 ampoule of 1ml contains 10mg methotrexate as active ingredient. 1 vial of 1ml contains 10mg methotrexate as active ingredient. 50mg methotrexate as active ingredient. 1 vial of 5ml contains 50mg methotrexate as active ingre